Cefoperazone sodium
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03920 |
| CAS | 62893-20-3 |
| Molecular Weight | 667.64 |
| Molecular Formula | C25H26N9NaO8S2 |
| Purity | ≥95% |
Online Inquiry
Description
Cefoperazone Sodium is a third generation cephalosporin antibiotic for inhibition of rMrp2-mediated [3H]E217βG uptake with IC50 of 199 μM, used in the treatment of bacterial infections caused by susceptible microorganisms.
Specification
| Related CAS | 62893-19-0 (free acid) |
| Synonyms | sodium;(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | Keep in a cool and dry place. |
| IUPAC Name | sodium;(6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Canonical SMILES | CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)[O-].[Na+] |
| InChI | InChI=1S/C25H27N9O8S2.Na/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2;/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41);/q;+1/p-1/t15-,16-,22-;/m1./s1 |
| InChI Key | NCFTXMQPRQZFMZ-WERGMSTESA-M |
| Source | Synthetic |
Properties
| Appearance | White to Off-white Solid |
| Application | Broad spectrum third generation cephalosporin antibiotic. An antibacterial. |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria |
| Melting Point | >180°C |
| Solubility | Soluble in DMSO |
Reference Reading
1.Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014.
Hu FP1, Guo Y1, Zhu DM1, Wang F2, Jiang XF3, Xu YC4, Zhang XJ4, Zhang CX5, Ji P5, Xie Y6, Kang M6, Wang CQ7, Wang AM7, Xu YH8, Shen JL8, Sun ZY9, Chen ZJ9, Ni YX10, Sun JY10, Chu YZ11, Tian SF11, Hu ZD12, Li J12, Yu YS13, Lin J13, Shan B14, Du Y14, Han Y1 Clin Microbiol Infect. 2016 Mar;22 Suppl 1:S9-S14. doi: 10.1016/j.cmi.2016.01.001.
With the aim of gathering temporal trends on bacterial epidemiology and resistance from multiple laboratories in China, the CHINET surveillance system was organized in 2005. Antimicrobial susceptibility testing was carried out according to a unified protocol using the Kirby-Bauer method or automated systems. Results were analyzed according to Clinical and Laboratory Standards Institute (CLSI) 2014 definitions. Between 2005 and 2014, the number of bacterial isolates ranged between 22 774 and 84 572 annually. Rates of extended-spectrum β-lactamase production among Escherichia coli isolates were stable, between 51.7 and 55.8%. Resistance of E. coli and Klebsiella pneumoniae to amikacin, ciprofloxacin, piperacillin/tazobactam and cefoperazone/sulbactam decreased with time. Carbapenem resistance among K. pneumoniae isolates increased from 2.4 to 13.4%. Resistance of Pseudomonas aeruginosa strains against all of antimicrobial agents tested including imipenem and meropenem decreased with time.
2.The resistance and transmission mechanism of Acinetobacter baumannii isolates in a tertiary care hospital, China.
Sun F1, Ou Q1, Wang Q2, Feng W1, Qiu X1, Chen J1, Liu Y1, Xia P1. J Chemother. 2016 Mar 30:1-6. [Epub ahead of print]
The aim of this study was to analyse the resistance and epidemiological data of 117 Acinetobacter baumannii isolates from Southwest Hospital, Chongqing, China. Except for polymyxin B, tigecycline, minocycline, cefoperazone/sulbactam, amikacin and levofloxacin, the resistance rates of other antimicrobial agents were above 90%. All the clinical isolates had the blaOXA-51 gene and 114 isolates had the blaOXA-23 gene. Forty-nine isolates were found to contain the blaIMP-4 gene. PFGE data showed that 117 isolates were divided into 25 groups. Sixty-three (53.85%) were found to carry the class 1 integron, and the sequence analysis of the class 1 integron internal variable regions - five types, one of which had the blaIMP-4 gene. For the blaIMP-4 positive strain without class 1 integron, we found the flanking sequence had the TnpA gene. The result suggested that the resistance gene was widely distributed in our hospital; moreover, the modes of presence and transmission are different and complicated.
3.Characterisation of drug resistance of nosocomial ESBL-producing E. coli isolates obtained from a Turkish university hospital between 2009 and 2012 by pulsed field gel electrophoresis and antibiotic resistance tests.
Karagöz A1, Sunnetcioglu M2, Ceylan MR2, Bayram Y3, Yalcin G4, Kocak N5, Suvak B6, Andac CA7. Infez Med. 2016 Mar 1;24(1):24-31.
In this study, drug resistance of 28 ESBL-producing Escherichia coli isolates obtained from 144 patients hospitalized at the Yüzüncüyil University Hospital at Van (YUH), Turkey, between 2009 and 2012 were characterized by pulsed field gel electrophoresis and antibiotic susceptibility tests. Antibiotic resistance profile was determined by Phoenix automated system (BD, USA). The ratio of ESBL-producing E. coli strains was determined to be 19.4% (28 out of 144 E. coli isolates). It was determined that the anaesthesiology, paediatrics and thoracic medicine intensive care units in YUH were cross-contaminated between 2009 and 2012 by ESBL-producing E. coli strains, which is a sign of nosocomial infection in YUH. Analysis of PFGE results gave rise to two main PFGE profiles, profile-A with four subprofiles and profile-B with three subprofiles, where profile-A predominates over profile-B (14%). Comparison of the antibiotic resistance profile with the PFGE profile yielded similarities while some differences also exist due to either identical restriction enzyme cutting sites with slightly different genetic sequences in between the cutting sites or newly formed restriction enzyme cutting sites that do not affect antibiotic resistance genes.
4.Molecular characterization of carbapenemase genes in Acinetobacter baumannii in China.
Fang F1, Wang S2, Dang YX3, Wang X3, Yu GQ3. Genet Mol Res. 2016 Mar 31;15(1). doi: 10.4238/gmr.15017432.
Acinetobacter baumannii is an aerobic non-motile Gram-negative coccobacillus, and it is one of the most important nosocomial pathogens worldwide. The aim of this study was to determine the molecular epidemiology of the outbreak strains. Between March 2011 and March 2014, a total of 205 strains of A. baumannii were isolated from patients at the Nanyang City Center Hospital. The blaOXA-23, blaOXA-24, blaOXA-51, and blaOXA-58 genes were amplified by multiplex polymerase chain reaction. We found that 68 (33.17%) strains were positive for the blaOXA-23 gene, and 88.24% of these 68 showed resistance to carbapenems, while 11.76% were sensitive to carbapenems. The blaOXA-51 gene was found in 132 (64.39%) strains, and 17.42% of these were resistant to carbapenems while 82.58% were sensitive to carbapenems. Moreover, 5 (2.44%) strains were positive for blaOXA-58, of which 80% were resistant to carbapenems and 20% were sensitive to carbapenems. We found that A.
Recommended Products
| BBF-03753 | Baicalin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-02614 | Nystatin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
